Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Participants

In brief

This first-in-human study, designed to assess the safety, tolerability, and pharmacokinetics (PK) of single oral ascending doses of E2027, will be administered to healthy adult participants to determine the maximum tolerated dose (MTD). Thereafter, the pharmacodynamic (PD) effects of single doses of E2027 on elevation of cerebrospinal fluid (CSF) cyclic guanidine monophosphate (cGMP) in healthy adult participants will be evaluated across a broad dose range, to establish the PK/PD relationship.

Key facts

Study ID

NCT02415790

Run by

Eisai Inc.

People needed

112

Starts

2015-07-01

Expected to finish

2016-07-01

Last updated by the study team

2017-03-08

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Part A and B only:
• Nonsmoking, male or female, age greater than or equal to 18 years and less than or equal to 50 years old at the time of informed consent
• Part C only:
• Nonsmoking, male or female, age greater than or equal to 65 years and less than or equal to 85 years old at the time of informed consent
• Part D only:
• Nonsmoking, male or female, age greater than or equal to 20 years and less than or equal to 50 years old at the time of informed consent
• Born in Japan to Japanese parents and grandparents of Japanese descent
• Been living outside Japan for less than 5 years
• Lifestyle, including diet, has not changed significantly since leaving Japan
• All parts:
• Body mass index (BMI) greater than or equal to 18 and less than or equal to 30 kg/m2 at Screening

You may not qualify if…

• Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing
• Females who are breastfeeding or pregnant at Screening or Baseline
• If females of childbearing potential who:
• Had unprotected sexual intercourse within 30 days before study entry and do not agree to use a highly effective method of contraception
• Are currently abstinent, and do not agree to use a double barrier method or refrain from sexual activity
• Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above. No sperm donation is allowed during the study period or for 28 days after study drug discontinuation.
• Evidence of disease that may influence the outcome of the study within 4 weeks before dosing
• Any history of abdominal surgery that may affect PK profiles of E2027
• Any clinically abnormal symptom or organ impairment found by medical history, physical examinations, vital signs, ECG finding, or laboratory test results that requires medical treatment at Screening or Baseline
• A prolonged QT/QTc interval (QTc greater than 450 ms) demonstrated on ECG at Screening or Baseline
• Persistent systolic blood pressure greater than 130 mmHg or diastolic blood pressure greater than 85 mm Hg at Screening or Baseline (Parts A, B, and D)
• Persistent systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mm Hg at Screening or Baseline (Part C)
• Heart rate less than 50 or more than 100 beats/min at Screening or Baseline
• History of prolonged QT/QTc interval
• Left bundle branch block
• History of myocardial infarction or active ischemic heart disease
• History of clinically significant arrhythmia or uncontrolled arrhythmia
• Known history of clinically significant drug allergy at Screening or Baseline
• Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening or Baseline
• Known to be human immunodeficiency virus (HIV) positive at Screening
• Active viral hepatitis (A, B or C) as demonstrated by positive serology at Screening
• History of drug or alcohol dependency or abuse within the 2 years before Screening, or those who have a positive urine drug or alcohol test at Screening or Baseline
• Intake of caffeinated beverages or food within 72 hours before dosing
• Intake of nutritional supplements, juice, and herbal preparations or other foods or beverages that may affect the various drug metabolizing enzymes and transporters within 1 week before dosing
• Intake of herbal preparations containing St. John's Wort within 4 weeks before dosing

Where it is running

• Paraxel International — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.